LIDDS: Update of News Release sent on November 9, 2019, with PDF-file: New Company Update and Market Valuation from Redeye
10 déc. 2019 02h30 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ)Redeye has published a new LIDDS Company Update and Market Valuation, see attached file. For additional information, please contact: Monica Wallter, CEO LIDDS, +46...
LIDDS: New Company Update and Market Valuation from Redeye
09 déc. 2019 08h30 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ)Redeye has published a new LIDDS Company Update and Market Valuation, see below link or PDF...
LIDDS Interview with the LPC-004 study investigator, Professor Laurence Klotz, about the LIDDS Liproca® Depot Phase IIb study results
02 déc. 2019 05h15 HE
|
LIDDS AB
An interview with Professor Laurence Klotz, one of the LPC-004 study investigators was done in connection to the 11th European Multidisciplinary Congress on Urological Cancers, EMUC19 in which he...
LIDDS Delårsrapport juli – September 2019
28 nov. 2019 02h30 HE
|
LIDDS AB
JULI – SEPTEMBER 2019Nettoomsättningen uppgick till 0,0 (7,8) MSEKKostnaderna uppgick till -2,8 (-2,5) MSEKResultatet före och efter skatt uppgick till -2,8 (5,4) MSEKResultat per aktie uppgick till...
LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met
16 nov. 2019 04h10 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) Phase IIb clinical data from the LPC-004 prostate cancer study on LIDDS Liproca® Depot were presented today in an oral session at the 11th European Multidisciplinary...
LIDDS completes a direct share issue raising SEK 9.0 million
15 nov. 2019 02h30 HE
|
LIDDS AB
The board of directors of LIDDS AB has decided to carry out a directed issue of 562,500 shares at a subscription price of SEK 16 per share. LIDDS will through the directed share issue receive proceeds...
LIDDS licensee Jiangxi Puheng Pharma prepares for phase III trial in China
07 nov. 2019 03h45 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) Jiangxi Puheng Pharma has after reviewing the preliminary results in LPC-004 decided to move ahead and has initiated discussions with Chinese medical authority, CFDA....
LIDDS adds Lithuanian clinics to phase I study
06 nov. 2019 02h45 HE
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) has received approval from authorities in Lithuania to conduct its Phase I study, NZ-DTX-001. Previously the phase I study is approved in Sweden and Denmark. The...
LIDDS: Liproca® Depot open label extension study indicates PSA reduction for up to one year
23 oct. 2019 02h30 HE
|
LIDDS AB
UPPSALA, SWEDEN. LIDDS AB (publ) – Data from a voluntary open label extension (OLE) study indicates longer PSA effect with Liproca® Depot in prostate cancer patients than anticipated. In half of the...
LIDDS: Wikow Invest is still the biggest shareholder in LIDDS (publ)
24 sept. 2019 13h00 HE
|
LIDDS AB
UPPSALA, SWEDEN. LIDDS AB (publ) – Due to a technical error by a market data provider, Wikow Invest was removed as largest shareholder in Top 10 tables at several trading and information sites over...